このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Opioid-Free Total Shoulder With Suzetrigine

2026年11月10日 更新者:OrthoCarolina Research Institute, Inc.

Opioid-Free Postoperative Analgesia With Suzetrigine Following Total Shoulder Arthroplasty: A Prospective Randomized Controlled Noninferiority Trial

This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.

調査の概要

状態

まだ募集していません

詳細な説明

Objective 1: To determine whether an opioid-free postoperative analgesic pathway utilizing suzetrigine provides noninferior postoperative pain control at 24 hours following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing postoperative analgesic pathway.

Hypothesis 1: Postoperative pain at 24 hours among patients randomized to the opioid-free suzetrigine pathway will be noninferior to postoperative pain among patients randomized to the standard opioid-containing pathway.

Objective 2: To compare postoperative opioid consumption, requirement for rescue opioid analgesia, time to first rescue opioid, postoperative pain scores, opioid-related adverse effects, and patient satisfaction between treatment groups.

Hypothesis 2: Patients randomized to the opioid-free suzetrigine pathway will have lower cumulative postoperative opioid consumption and reduced need for rescue opioid analgesia without clinically meaningful worsening of postoperative pain, or patient satisfaction.

Objective 3: To evaluate the safety profile of suzetrigine following total shoulder arthroplasty by characterizing adverse events, medication-related adverse effects, drug-drug interactions, treatment discontinuation, emergency department visits, unplanned readmissions, and reoperations.

Hypothesis 3: Patients randomized to the opioid-free suzetrigine pathway will have lower rates of opioid-related adverse events, including sedation, respiratory depression, nausea, and constipation, compared with patients randomized to the standard opioid-containing pathway.

Objective 4: To evaluate shoulder-specific functional outcomes and determine whether preoperative patient resilience is associated with postoperative pain control, opioid requirements, rescue opioid use, and patient satisfaction.

Hypothesis 4: Shoulder-specific patient-reported outcomes will be comparable between treatment groups. Greater preoperative resilience, as measured by the CD-RISC-10, will be associated with lower postoperative pain, reduced opioid consumption, decreased need for rescue opioid analgesia, and greater satisfaction with pain control.

研究の種類

介入

入学 (推定)

52

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age ≥18 years
  2. Undergoing elective primary anatomic or reverse total shoulder arthroplasty
  3. English-speaking (for patient-reported outcome assessments)

Exclusion Criteria:

  1. Revision arthroplasty procedures

  2. Total shoulder arthroplasty performed for a fracture-related indication, including acute fractures and chronic fracture sequelae (e.g., malunion or nonunion)

  3. History of chronic opioid use (defined as daily or near-daily use for ≥90 days preoperatively)

  4. Contraindications to suzetrigine:

    1. Known allergy or hypersensitivity to suzetrigine
    2. Current use of strong CYP3A inhibitors (contraindicated per FDA labeling)
    3. Current use of strong or moderate CYP3A inducers (should be avoided per FDA labeling)
    4. Severe hepatic impairment (Child-Pugh Class C)
    5. Severe renal impairment (eGFR <15 mL/min/1.73 m²)
  5. Pregnancy or breastfeeding

  6. Inability to complete patient-reported outcome measures

  7. Simultaneous bilateral arthroplasty

  8. Unable or unwilling to provide informed consent or comply with study procedures

  9. Total shoulder arthroplasty performed for an oncologic indication

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Standard Opioid-Containing Pathway

Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

実験的:Opioid-Free Suzetrigine Pathway

Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pain Numeric Rating Scale (NRS)
時間枠:24 hours post-surgery

The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at 24 hours following surgery.

24 hours post-surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Pain Numeric Rating Scale (NRS)
時間枠:From enrollment to the end of treatment at 1 year

The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain)

From enrollment to the end of treatment at 1 year
Morphine Milligram Equivalents (MME)
時間枠:24 hours postoperative

Cumulative opioid consumption converted to MME

24 hours postoperative
Morphine Milligram Equivalents (MME)
時間枠:48 hours postoperative

Cumulative opioid consumption converted to MME

48 hours postoperative
Rescue opioid analgesia
時間枠:From enrollment to the end of treatment at 1 year

Requirement for rescue opioid analgesia (yes/no)

From enrollment to the end of treatment at 1 year
Patient satisfaction with overall pain control
時間枠:From enrollment to the end of treatment at 1 year

Patient satisfaction with overall pain control, measured on a scale of 0-10 with 0 being less satisfied and 10 being completely satisfied.

From enrollment to the end of treatment at 1 year
Hospital length of stay
時間枠:At the time of surgery treatment.

Time spent in hospital

At the time of surgery treatment.
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
時間枠:From enrollment to the end of treatment at 1 year

The American Shoulder and Elbow Surgeons Shoulder Score (ASES) was designed to assess the condition of the shoulder, regardless of disease pathology.

The ASES is a composite instrument, requiring both a physician assessment and a patient-completed portion; however, it is commonly presented as solely the patient-reported survey. This includes a section on pain (7 items) and a section on activities of daily living (10 items). Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.

From enrollment to the end of treatment at 1 year
Single Assessment Numeric Evaluation (SANE)
時間枠:From enrollment to the end of treatment at 1 year

Patients are asked: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being a completely normal shoulder)?"

From enrollment to the end of treatment at 1 year
Simple Shoulder Test (SST)
時間枠:From enrollment to the end of treatment at 1 year

Self-reported questionnaire that evaluates shoulder function, comfort, and strength through simple "yes" or "no" questions that result in 0% (worst function) to 100% (best function) score.

From enrollment to the end of treatment at 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Nady Hamid, MD、OrthoCarolina Research Institute, Inc.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する